SPW
UTHR icon

Signet Private Wealth’s United Therapeutics UTHR Stock Holding History

Signet Private Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Sell
376
-37
-9% -$20.8K 0.16% 121
2026
Q1 		$245K Sell
413
-14
-3% -$6.97K 0.23% 105
2025
Q4 		$208K Buy
+427
New +$199K 0.2% 115

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Signet Private Wealth's UTHR Position: Q2 2026 in Review

Signet Private Wealth reduced its United Therapeutics (UTHR) stake by 9% in Q2 2026, selling an estimated $20.8K and leaving 376 shares worth $204K. The position accounts for 0.16% of the portfolio, ranked #121.

Signet Private Wealth first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $245K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Signet Private Wealth held 376 shares of United Therapeutics worth $204K as of Q2 2026.
  • Signet Private Wealth sold 37 United Therapeutics shares in Q2 2026, an estimated $20.8K.
  • United Therapeutics made up 0.16% of Signet Private Wealth's portfolio in Q2 2026, its #121 holding.
  • Signet Private Wealth first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Signet Private Wealth's United Therapeutics position peaked at $245K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Signet Private Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.